Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,437 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.4
Industry P/E
--
EV/EBITDA
-4.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$1.4
EPS
$-0.3
Face value
--
Shares outstanding
128,397,271
CFO
$-178.38 Mln
EBITDA
$-184.16 Mln
Net Profit
$-195.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| -4.6 | 0.2 | -4.6 | 98.7 | 86.2 | 34.1 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| 203.9 | 204.7 | -30.6 | 146.8 | -67.7 | -35.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
|
11.9 | 1,436.8 | 0.0 | -42.8 | -- | -30.2 | -- | 7.4 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease,... and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510 Read more
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
Headquarters
New Haven, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Trevi Therapeutics Inc (TRVI) is $11.94 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Trevi Therapeutics Inc (TRVI) has given a return of 86.18% in the last 3 years.
Since, TTM earnings of Trevi Therapeutics Inc (TRVI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-39.53
|
9.22
|
|
2024
|
-8.77
|
4.22
|
|
2023
|
-4.56
|
1.61
|
|
2022
|
-4.30
|
1.17
|
|
2021
|
-0.53
|
1.05
|
The 52-week high and low of Trevi Therapeutics Inc (TRVI) are Rs 14.39 and Rs 4.85 as of 04-Apr-2026.
Trevi Therapeutics Inc (TRVI) has a market capitalisation of $ 1,437 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Trevi Therapeutics Inc (TRVI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.36
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.